The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis

Thrombosis Research

Volumn 120, Issue 2, 2007, Pages 215-220

  Carrier, Marc ^a   Knoll, Greg A ^a,b   Kovacs, Michael J ^c   Moore, Jane C ^d   Fergusson, Dean ^b   Rodger, Marc A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Case control study; Hemodialysis; Heparin platelet factor 4 antibodies; Prevalence; Vascular access thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; WARFARIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING TEST; THROMBOSIS; VASCULAR ACCESS;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEPARIN; HUMANS; MACROMOLECULAR SUBSTANCES; MALE; MIDDLE AGED; PLATELET FACTOR 4; RENAL DIALYSIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 34248573447     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.09.014     Document Type: Article

References (31)

1. Simioni P., Prandoni P., Burlina A., Tormene D., Sardella C., Ferrari V., Benedetti L., and Girolami A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 76 (1996) 883-886
2. Muntner P., Hamm L.L., Kusek J.W., Chen J., Whelton P.K., and He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140 (2004) 9-17
3. Feldman H.I., Kobrin S., and Wasserstein A. Hemodialysis Vascular Access Morbidity. J Am Soc Nephrol 7 (1996) 523-535
4. Schwab S.J. Vascular Access for Hemodialysis. Kidney Int 55 (1999) 2078-2090
5. Yamamoto S., Koide M., Matsuo M., Suzuki S., Ohtaka M., Saika S., and Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28 (1996) 82-85
6. Boon D.M., van Vliet H.H., Zietse R., and Kappers-Klunne M.C. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 76 (1996) 480
7. Sitter T., Spannagl M., Banas B., and Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 79 (1998) 245-246
8. Greinacher A., Zinn S., Wizemann, and Birk U.W. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 348 (1996) 764
9. Luzzatto G., Bertoli M., Cella G., Fabris F., Zaia B., and Girolami A. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 89 (1998) 115-122
10. Yu A., Jacobson S.H., Bygden A., and Egberg N. The presence of heparin-platelet factor 4 antibodies as a marker of hypercoagulability during hemodialysis. Clin Chem Lab Med 40 (2002) 21-26
11. Mureebe L., Coats R.D., Silliman W.R., Shuster T.A., Nichols W.K., and Silver D. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 136 (2004) 848-853
12. Knoll G.A., Wells P.S., Young D., Perkins S.L., Pilkey R.M., Clinch J.J., and Rodger M.A. Thrombophilia and the risk of hemodialysis vascular access thrombosis. J Am Soc Nephol 16 (2005) 1108-1114
13. Warkentin T.E., and Sheppard J.I. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 4 (2006) 281-282
14. Warkentin T.E., Sheppard J.I., Moore J.C., Moore K.M., Sigouin C.S., and Kelton J.G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Med 146 (2005) 341-346
15. Sheridan D., Carter C., and Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 67 (1986) 27-30
16. Warkentin T.E., Hayward C.P.M., Smith C.A., Kelly P.M., and Kelton J.G. Determinant of donor platelet variability when testing for heparin-induced thrombocytopenia. J Clin Med 120 (1992) 371-379
17. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., Weltermann A., Speiser W., Lechner K., and Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
18. Tripodi A., Chantarangkul V., Lombardi R., Lecchi A., Mannucci P.M., and Cattaneo M. Multicenter study of homocysteine measurement-performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost 85 (2001) 291-295
19. McNeil H.P., Chesterman C.N., and Krilis S.A. Immunology and Clinical Importance of antiphospholipid Antibodies. Adv Immunol 49 (1991) 193-280
20. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A., and Khamashta M.A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
21. Pena de la Vega L., Miller R.S., Benda M.M., Grill D.E., Johson M.G., MacCarthy J.T., and McBane R.D. Association of Heparin-Dependent Antibodies and Adverse Outcomes in Hemodialysis Patients: a Population-Based Study. Mayo Clin Proc 80 (2005) 995-1000
22. Mattioli A.V., Bonetti L., Sternieri S., and Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 1 (2000) 39-42
23. Williams R.T., Damaraju L.V., and Mascelli M.A. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107 (2003) 2307-2312
24. Nakamoto H., Shimada Y., Kanno T., Wanaka K., Matsuo T., and Suzuki H. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9 (2005) S2-S7
25. Kelton J.G., and Warkentin T.E. Heparin-induced thrombocytopenia: what the serologist have taught us. J Lab Clin Med 128 (1996) 346-348
26. Luzzatto G., Cordiano I., Patrassi G., and Fabris F. Heparin induced thrombocytopenia: discreptancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use. Thromb Haemost 74 (1995) 1607-1608
27. Lindhoff-Last E., Gerdsen F., Ackermann H., and Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 113 (2001) 886-890
28. Crowther M.A., and Kelton J.G. Congenital Thrombophilic States Associated with Venous Thrombosis: a Qualitative Overview and Proposed Classification System. Ann Intern Med 138 (2003) 128-134
29. Schwab S. Hemodialysis Vascular Access: an Ounce of Prevention. Kidney Int 52 (1997) 1704-1705
30. May R.E., Himmelfarb J., Yenicesu M., Knights S., Ikizler T.A., Schulman G., Hernanz-Schulman M., Shyr Y., and Hakim R.M. Predictive Measures of Vascular Access Thrombosis: a Prospective Study. Kidney Int 52 (1997) 1656-1662
31. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292